NZ331844A

NZ331844A - A disintegrin metalloprotease and use in diagnosis of disease or treatment of arthritis

Info

Publication number: NZ331844A
Application number: NZ331844A
Authority: NZ
Inventors: Michael Howard Tindal; Tariq Haqqi
Original assignee: Univ Case Western Reserve; Procter & Gamble
Priority date: 1996-03-01
Filing date: 1997-02-28
Publication date: 2000-06-23
Also published as: KR19990087444A; CA2247827A1; JPH11506023A; EP0888375A1; EP0888375A4; NO983984L; NO983984D0; WO1997031931A1; AU2061797A

Abstract

A method for identifying compounds capable of binding to the disintegrin protein, and determining the amount and affinity of a compound capable of binding to the disintegrin protein in a sample. A host cell comprising a recombinant expression vector to the disintegrin protein and a recombinant expression vector encoding to the disintegrin protein and the human disintegrin metalloprotease protein, fragment or mutant thereof, useful for these purposes. An in vivo or in vitro method for screening for osteoarthritis and other metalloprotease based diseases, capable of manufacture and use in a kit form.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 331 844 % (51) Classification: A61K38/00, A61K39/39S, C07H21/02, C07K14/435, C12N15/63, C12N5/16, G01N33/53 Intellectual Property Office of New Zealand IP Summary Report IPC Edition: IPC Status: 70 Accepted Client Ref: P395659 KCT/jaa Page: 1 of 1 Date: 22 May 2000 Time: 13:05:40 (Inrip02 2.00.21) 331844 Version number: 4 IP type: Patent PCT Inward (86) International Application number: US97/03217 (87) WO Publication number: 97/31931 Elected: N Date actions completed: Application Accepted 22 May 2000 Next renewal date: 28 February 2001 (22) NZ Filing date: 28 February 1997 Date entered National phase: 11 September 1998 (30) Priority Data: (31)96 12679 (32) 01 March 1996 (33) US (71) Applicants: CASE WESTERN RESERVE UNIVERSITY, School of Medicine, 10900 Euclid Avenue, Cleveland, Ohio 44106-4946, United States of America THE PROCTER & GAMBLE COMPANY, One Procter & Gamble Plaza, Cincinnati, Ohio 45202, United States of America (72) Inventors: Tindal, Michael Howard Haqqi, Tariq Contact: A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington, New Zealand Primary Examiner: SIMON SAUNDERS Journal: 1452 Office title: A dislntegrin metalloprotease and use In diagnosis of disease or treatment of arthritis (54) Applicant title: A novel dislntegrin metalloprotease and methods of use (57) Abstract: Patent 331844 A method for identifying compounds capable of binding to the disintegrin protein, and determining the amount and affinity of a compound capable of binding to the disintegrin protein in a sample. A host cell comprising a recombinant expression vector to the disintegrin protein and a recombinant expression vector encoding to the disintegrin protein and the human dislntegrin metalloprotease protein, fragment or mutant thereof, useful for these purposes. An in vivo or in vitro method for screening for osteoarthritis and other metalloprotease based diseases, capable of manufacture and use in i kit form. " End of repoit " WO 97/31931 PCT/US97/03217 A NOVEL DISINTEGRIN METALLOPROTEASE AND METHODS OF USE field of ths invention The invention relates to a novel protein, its fragments and mutants and to its use in detecting and testing drugs for ailments, including osteoarthritis and others characterized by up regulation of metaiioproteases. Background A number of enzymes effect the breakdown of structural proteins and are isructurally related mej$||pp£rt3U63. These include human skin fibroblast collsgenase, hiwiian slcin fibroblast gelatinase, human sputum collagenase and gelatinase, and human stromelysin. These are zinc-containing metalloprotease enzymes, as are the angiotensin-converting enzymes and the enkephalinases. Collagenase, stromeiysin and related enzymes are important in mediating the symptomatology of a number of diseases, including rheumatoid arthritis (Mullins, D. E., et al., Biochim Biophys Acta (1983) 695:117-214); osteoarthritis (Henderson, B , et al., Drugs of the Future (1990) 15:495-508); the metastasis of tumor ceils (ibid, Broadhurst, M. J., et al., European Patent Application 276,436 (published 1987), Reich, R., et al., 48 Cancer Res 3307-3312 (1988); and various ulcerated conditions. Ulcerative conditions can result in the cornea as the result of alkali burns or as a result of infection by Pseudomonas aeruginosa, Acsnthamoeba, Herpes simplex and vaccinia viruses. Other conditions characterized by undesired metalloprotease activity include periodontal disease, epidermolysis bullosa and sderitis. In view of the involvement of metaiioproteases in-a number of disease conditions, attempt* have been made to prepare inhibitors to these enzymes. A VXtbet of such inhibitors are disclosed in the literature. The invention seeks to provide novel inhibitors, preferably specific to this protease, that have enhanced activity in treating diseases mediated or modulated by this protease. Inhibitors of metaiioproteases are useful in treating diseases caused, al least in part, by breakdown of structural proteins. A variety of inhibitors have been prepared, but there is a continuing need for metalloprotease inhibitor screens to design drugs for treating such diseases. Metaiioproteases are a broad class of proteins which have widely varied functions Disintegrate are zinc metaiioproteases, abundant in snake venom. Alternate cloning strategies could be used. Mammalian disintegrins are a family of proteins with about 18 Printed from Mimosa WU 97/31931 PCT/US57/03217 2 known subgroups. They act as cell adhesion disrupters and are also known to be active in reproduction (for example, in fertilization of the egg by the sperm, including fusion thereof, and in sperm maturation). These proteases and many others are uncovered in molecular biology and biochemistry As a result, Genbank, a repository for gene sequences, provides several sequences of metaiioproteases, including some said to encode fragments of disintegrins. For example, GenBank accession # Z48444 dated February 25, 1994 discloses 2407 bases of a rat gene said to be a rat disintegrin metalloprotease gene; GenBank accession # Z48579 dated March 2, 1995 discloses 1824 bases of a partial sequence of a gene said to be a human disintegrin metalloprotease gene; GenBank accession # Z21961 dated October 25,1994, discloses 2397 bases of a partial sequence of a gene said to be a bovine zinc metalloprotease gene. It would be advantageous to implicate metaiioproteases in specific disease states, and to use these metaiioproteases as tools to detect and ultimately cure, control or design cures for such diseases. OBJECTS OF THE INVENTION The objects are those of various preferred embodiments of the invention. It is not necessary for any one embodiment of the invention to satisfy all stated objects. It is an object of the present invention to provide a method for identifying compounds capable of binding to the disintegrin protein. It is also an object of the present invention to provide a host cell comprising a recombinant expression vector to the disintegrin protein and a recombinant expression vector encoding to the disintegrin protein. It is also an object of the present invention to provide a method for screening for metalloprotease mediated diseases such as cancer, arthropothies (including ankylosing spondoiytia, rheuxnatiod arthritis, gouty arthritis (gout), inflammatory arthritis, Lyme disease and osteoarthntis). It is also an object of the present invention to provide an antibody to the protein usefiil ia the screen, in the isolation of the protein or as a targeting moiety for the protein. SUMMARY OF THE INVENTION This invention provides a method for identifying compounds capable of binding to the disintegrin prater., and determining the amount and affinity of a compound capable of binding to the disintegrin protein in a swnple. This invention also provides a host cell comprising a recombinant expression vector to the disintegrin protein and a recombinant expression vector encoding to the disintegrin protein and the human disintegrin metalloprotease protein, fragment or mutant thereof useful for these purposes. I inteu£CT1jal property office 0FN2. 10 APR 2000 RECEIVED 3 (followed by 3A) ^ ^ 3 U "!f ^ This invention also provides an in vivo or in vitro method for screening for osteoarthrtis and other metalloprotease based diseases, such as cancer, capable of manufacture and use in a kit form. In one aspect, the invention as claimed consists in an isolated nucleic acid comprising a nucleotide sequence encoding the human disintegrin of SEQ ID NO:4 or a functionally equivalent fragment thereof. In a second aspect, the invention as claimed consists in a human disintegrin comprising an amino acid sequence which is the amino .icid sequence as set forth in SEQ ID NO:4, or a functionally equivalent fragment thereof, in essentially pure form. In a third aspect, the invention consists in the use of a disintegrin inhibitor in the manufacture of a medicament for treating a disease state associated with distintegrin activity. Other aspects of the invention are covered by the following description and by the claims. DETAILED DESCRIPTION As used herein, the terms "protein," "protease," and "metalloprotease" refer to a disintegrin. Preferably this is a human disintegrin as described below The term "antibody" refers to an antibody to a disintegrin, or fragment thereof. These many be monoclonal or polyclonal, and can be from any of several sources. The invention also contemplates fragments of these antibodies made by any method in the protein or peptide art. The term "disease screen" refers to a screen for a disease or disease state A disease state is the physiological or cellular or biochemical manifestation of the disease. Preferably this screen is used on body tissues or fluids of an animal or cell culture, using standard techniques, such as ELiSA. It also contemplates "mapping" of disease in a whole body, such as by labeled antibody as described above given systemically: regardless of the detection method, preferable such detection methods include fluorescence, X-ray (including CAT scan), NMR (Including MRI), and the like. The term "compound screen" is related to the methods and screens related to finding compounds, determining their affinity for the protease, or designing or selecting compounds based on the screen. In another embodiment, it contemplates the use of the three dimensional structure for drug design, preferable "rational drug design", as understood by the art. It may be preferred that the protease is in "essentially pure form", which refers to a protein reasonably free of other impurities, so as to make it useful for experiments or characterization. Use of this screening method assists the skilled artisan in finding novel structures, whether made by the chemist or by nature, which bind to and preferably inhibit the protease. These "inhibitors" may be useful in regulating or modulating the activity of the protease, and may be used to thus modulate the biological cascade that they function in. This approach affords new pharmaceutically useful compounds. INTELLECTUAL PROPERTY OFFICE OF N.Z. - 1 MAY 2000 DCOru/rn The term "disintegrin" refers to a disintegrin, a fragment thereof a mutant thereof or a horaologue which still retains its function. This term contemplates aggracanase, and other proteases which are involved in or modulate tissue remodelling. This contemplates disintegrins from differing species, and those prepared by recombinant methods, in vitro methods, or standard peptide synthesis. Preferably the protein is a human disintegrin or mutant thereof. Fcr the purposes of defining the mutants of the protein the preferred > intellectual property office of n2. -1 MAY 2000 RECEIVED WO 97/31931 PCT/US97/03217 4 "native" protein is described in GenBank accession # Z48S79, incorporated herein by reference and referred to in the sequence below. SEQ ID NO 1 describes a fragment of that DNA sequence and its transcript and S£Q ID NO 2 describes the coding region of the gene and its transcript Homologue disintegrins include whole proteins with at least 90% homology as understood by the art, or fragments thereof. For example, a rat protein which is 95% homologous to that of SEQ ID NO. 1 or SEQ ID NO. 2 based on the peptide sequence derived from the DNA or cDNA sequence, and a bovine protein (similarly derived) being 97-98% homologous, are both considered homologues. Thus homologous cDNAs cloned from other organisms give rise to homologous proteins. Likewise proteins may be considered homologues based on the amino acid sequence alone. Practical limitations of amino acid sequencing would allow one to determine that a protein is homologous to another using for example comparison of the first SO amino acids of the pro*'*u. Hence 90% homology in would allow for 5 differing amino acids in the chain of tne first SO amino acids of the homologous protein. The skilled artisan will appreciate that the degeneracy of the genetic code provides for differing DNA sequences to provide the same transcript, and thus the same peptide. In certain cases preparing the DNA sequence, which encodes for the same peptide, but differs from the native DNA include; — ease of sequencing or synthesis; — increased expression of the peptide; and — preference of certain heterologous hosts for certain codons over others. These practical considerations are widely known and provide embodiments that may be advantageous to the user of the invention. Thus it is clearly contemplated that the native DNA is not the only embodiment envisioned in this invention. In addition it is apparent to the skilled artisan that fragments of the protein may be used in screening, drug design and the like, and that the entire peptide may not be required for the purposes of using the invention. Thus it is clearly contemplated that the skilled artisan will understand that the disclosure of the peptide and its uses contemplates the useftil peptide fragments. The practical considerations of protein expression, purification yield, stability, solubility, and the like, are considered by the skilled artisan when choosing whether to use a fragment, and the fragment to be used. As a result, using routine practices in the art, the artisan can, given this disclosure practice the invention using fragments of the protein as well. Printed from Mimosa WO 97/31931 PCT/US97/032n 5 The protein or protease itself can be used to determine the binding '. tivity of small molecules to the protein. Drug screening using enzymatic targets is used in the art and can be employed using automated, high throughput technologies. The inhibition of disintegrin activity may be a predictor of efficacy in the treatment of osteoarthritis, and other diseases involving degeneration of articular cartilage. Oen<? thyqpy Without being bound by theory it is thought that the metalloprotease is up regulated during osteoarthritis in tissues. We have surprisingly fount' that a human disintegrin is up-regulated in human chondrocytes during osteoarthr.uc conditions. Inhibition of signal transduction mechanism is efficacious in disrupting the cascade of events in osteoarthritis and other diseases involving cartilage degeneration. The skilled artisan will recognize that if up-regulation is a cause of the onset of anhritis, then interfering with the activity of this gene may be useful in treating osteoarthritis. This is done by any of several methods, including gene (i.e., antisense) therapy. Inhibitors of the disintegrin The protease of the invention can be used to find inhibitors of the protease. Hence it is useful as a screening tool or for rational drug design. Without being bound by theory, the protease may modulate cellular remolding and in fact may enhance extracellular matrix remodeling and thus enhance tissue breakdown.. Hence inhibition of disintegrin provides a therapeutic route for treatment of diseases characterized by these processes. In screening, a drug compound can be used to determine both the quality and quantity of inhibition. As a result such serening provides information for selection of actives, preferably small molecule actives, which are usefiil in treating these diseases. In therapy, inhibition of disintegrin metalloprotease activity via binding of small molecular weight, synthetic metalloprotease inhibitors,, such as those used to inhibit the matrix metaiioproteases would be used to inhibit extracellular matrix remodeling. Amitodta tg the proton Metaiioproteases active at a particularly undesired location (e.g., an organ or certain types of cells) can be targeted by conjugating a metalloprotease inhibitor to a to an antibody or fragment thereof. Conjugation methods are known in the art The antibody of the invention can also be conjugated to solid supports. These conjugates can be used as affinity reagents for the purification of a desired metalloprotease, preferably a disintegrin. Printed from Mimosa WO 97/31931 PCT/US97/03217 6 In another aspect, the antibody of the invention is directly conjugated to a label. As the antibody binds to the metalloprotease, the label can be used to detect the presence of relatively high levels of metalloprotease in vivo or in vitro cell culture. In addition, the metalloprotease inhibiting compounds can be conjugated to antibodies. Typical conjugation methods are known in the ait. These antibodies are then useful both in therapy and in monitoring the dosage of the inhibitors. For example, targeting ligand which specifically reacts with a marker for the intended target tissue can be used. Methods for coupling the invention compound to the targeting ligand are well known and are similar to those described below for coupling to carrier. The conjugates are formulated and administered as described above. Preparation and Use of Antibodies: Antibodies may be .~iade by several methods, for example, the protein may be injected into suitable (e.g., mammalian) subjects including mice, rabbits, and the Hke. Preferred protocols involve repeated injection of the immunogen in the presence of adjuvants according to a schedule which boosts production of antibodies in the serum. The titers of the immune serum can readily be measured using immunoassay procedures, now standard in the art. The antisera obtained can be used directly or monoclonal antibodies may be obtained by harvesting the peripheral blood lymphocytes or the spleen of the immunized animal and immortalizing the antibody-producing cells, followed by identifying the suitable antibody producers using standard immunoassay techniques. Polyclonal or monoclonal preparations are useful in monitoring therapy or prophylaxis regimens involving the compounds of the invention. Suitable samples such as those derived from blood, serum, urine, or saliva can be tested for the presence of the protein at various times during the treatment protocol using standard immunoassay techniques which, employ the antibody preparations of the invention. These antibodies can also be coupled to labels such as scintigraphic labels, e g , technetium 99 or 1-131, using standard coupling methods. The labeled compounds are administered to subjects to determine the locations of excess amounts of one or more metaiioproteases in vivo. Hence a labelled antibody to the protein would operate a a screening tool for such enhanced expression,, indicating the disease. The ability of the antibodies to bind metalloprotease selectively is thus taken advantage of to map the distribution of these enzymes in situ. The techniques can also be employed in histological procedures and the labeled antibodies can be used in competitive immunoassays. Printed from Mimosa WO 97/31931 PCT/US97/03217 Antibodies ire advantageously coupled to other compounds or materials using known methods. For example, materials having a carboxyl functionality, the carboxyl residue can be reduced to an aldehyde and coupled to carrier through reaction with side chain amino groups, optionally followed by reduction of imino linkage formed. The carboxyl residue can also be reacted with side chain amino groups using condensing agents such as dicyclohexyl carbodiimide or other carbodiimide dehydrating agents. Linker compounds can also be used to effect the coupling; both homobtfiinctional and heterobifonctional linkers are available from Pierce Chemical Company, Rockford, 111. These antibodies, when conjugated to a suitable chromatography material are useful in isolating the protein. Separation methods using affinity chromatography are well known in the art, and are vrithin the purview of the skilled artisan. Disease marker Without being bound by theory, expression of genes, and preferably this gene may have a restricted tissue distribution and its expression is up regulated by potential osteoarthritis mediators. Enhanced expression of this gene (and hence its protein) for example, in articular chondrocytes provides a marker to monitor the development, including the earliest, asymptomatic stages, and the progression of osteoarthritis. Hence an antibody raised to the protein would operate a a screening tool for such enhanced expression, indicating the disease. In addition, when used in a disease screen, antibodies can be conjugated to chromophore or fluorophore containing materials, or can be conjugated to enzymes which produce chromophores or fluorophores in certain conditions. These conjugating materials and methods are well known in the art. When used in this manner detection of the protein by immunoassay is straightforward to the skilled artisan. Body fluids, for example can be screened in this manner for calibration, and detection of distribution of metaiioproteases, or increased levels of these proteases. When used in this way the invention is a useful diagnostic and/or clinical marker for metalloprotease mediated diseases, such as osteoarthritis or other articular cartilage degenerative diseases. When disease is detected, it may be treated before the onset of symptom or debilitation. Furthermore, such antibodies can be used to target diseased tissue, for detection or treatment as described above. EXAMPLES The following non-limiting examples illustrate a preferred embodiment of the present invention, and briefly describe the uses of the present invention. These Printed from Mimosa WO 97/31931 PCT7US97K)3217 8 examples are provided for the guidance of the skilled artisan, and do not limit the invention in any way. Armed with this disclosure and these examples the skilled artisan is capable of making and using the claimed invention. Standard starting materials are used for these examples. Many of these materials are known and commercially available. For example E. coli CJ236 and JM101 are known strains, pUBl 10 is a known plasmid and Kunkel method mutagenesis is also well known in the art. Variants may be made by expression systems and by various methods in various hosts, these methods are within the scope of the practice of the skilled artisan in molecular biology, biochemistry or other arts related to biotechnology. Bramptel RNA was isolated from unstimulated and interleukin-1 stimulated cultures of normal human articular chondrocytes. The RNA was reverse transcribed into cDNA. The cDNA was subjected to a modified differential display procedure using a series of random primers. PCR samples generated from both stimulated and unstimulated chondrocytes were electrophoreses in adjacent lanes on polyacrylamide gels. The differentially expressed band was excised from the gel, cloned, snd sequenced. The differential expression of the gene was confirmed by RNase protection and nuclear run on experiments. Example 2 A novel partial human cDNA coding the protein is cloned from primary cultures of interleukin-1 stimulated human articular (femoral head) chondrocytes, using known methods. The same sequence is found, and the gene completed by screening of human cDNA libraries to obtain full length clones. Eximpte? The cloned DNA of example 2 was placed in pUBHO using known methods. This plasmid is used to transform £ coli and provides a template for site-directed mutagenesis to create new mutants. Kunkel method mutagenesis performed altering GLN 1 ALA. Example 4 fl25^ disintegrin antibody is prepared using IODOBEADS (Pierce, Rockfbrd, IL; immobilized chloramine-T on nonporous polystyrene beads). LyophiUzed antibody (2 |*g) is taken up in 50 |il of 10 mM acetic acid and added to 450 pi of phosphate-buffered saline (PBS) (Sigma, St. Louis, MO) on ice. To the tube is added 500 pCurie of1251 Printed from Mimosa wo 97/31931 PCT/U897/D3217 (Amersham, Arlington Heights, EL) (2200Ci/mmol) in 5 jil, and one IODOBEAD. The reaction is incubated on ice for 10 min with occasional shaking. The reaction is then terminated by removal of the reaction from the IODOBEAD. To remove unreacted the mixture is applied to a PD-10 gel filtration column. Eximpte? A fluorogenic peptide (Bachem, Gutiph Mills, King of Prussia, Pa) is mixed with the disintegrin and change in the fluorecence is evaluated at 2 min, as a control.. Then the fluorogenic peptide is mixed with the disintegrin in the presence of the compound in evaluation in a separate run, with evaluation at 2 minutes. Data are evaluated using standard methodology to provide relative binding of the evaluated compound. EwmpteC 0.5ml of synovial fluid from tht left knee of a patient is withdrawn and tested for elevated levels disintegrin by ELISA. The results indicate higher than nonnal disintegrin level. The patient is prescribed a prophylactic dose of a disintegrin inhibitor, and is administered an injection of same in the left knee before leaving the clinician's office. Ftfiynpla7 Inhibition of extracellular matrix remodeling is explored via inhibition of disintegrin metalloprotease activity. Using a small molecular weight, synthetic metalloprotesse inhibitor, such as those used to inhibit the matrix metaiioproteases, tissue integrety and proteoglycan is monitored. A sample of mouse derived articular cartilage is grown in a 1 tnicromolar solution of a small molecular weight disintegrin inhibitor. The experiment is controlled and compared to an identical culture grown with no inhibitor. The assay of the culture after 7 days shows that the inhibited culture has less tissue breakdown and leu proteoglycan present in the serum of the culture. The result is coniistant with the inhibited aggrecanase activity. Inhibition of aggrecanase would inhibit tissue breakdown and reduce the release of proteoglycan. Inhibition of proteolytic processing resulting in the release from the membrane bound form of the disintegrin metalloprotease domain inhibits "second messenger" signaling of the membrane bound disintegrin molecule. Such second messenger signaling would result in cellular phenotypic changes, changes in gene expression, changes in mitotic activity, and the like. Ceils known to contain disintegrin are treated with a serine protease. Proteins released from the cell are measured by standard methods. Specifically the Printed from Mimosa WO 97/31931 PCT/US97/03217 10 metalloprotease activity is monitored via literature methods. The amount of metalloprotease released is correlated to the amount of serine protease used to treat the cells. Increaeses, versus control, in src tyrosine kinase activity are measured by Western blot analysis of intracellular proteins using monoclonal antibodies specific for phosphotyrosine following cleavage and release of the disintegrin metalloprotease. Controls are cells that have not been treated with serine protease. src tyrosine kinase activity in the cell (or is it cell culture) is measured by literature meathods. Release of the metalloprotease domain of the disintegrin is also monitored via literature methods. There is a direct correlation between release of the metalloprotease domain and increases in intracellular src tyrosine kinase activity. This result is consistent with stimulation of disintegrin-mediated cell signalling by stimulation of the src tyrosine kinase cascade. Example 9 Inhibition of intercellular adhesion molecules, or extracellular matrix components results in the inhibition of phenotypic changes, including changes in cell shape, associated with such interactions, as described in Example 8. Integrin binding is measured with a peptide containing the sequence RGD, using the protocol of Example 8. Integrin binding is measured via competitive assay, using cellular changes in shape visible via microscopy. The peptide inhibits the cellular changes as in Example 8. This result is consistent with competition with or blocking of the interaction of disintegrin. The RGD peptide inhibits cellular changes in chondrocytes. The osteoarthritis phenotype, characterized by increased matrix synthesis and accelerated matrix metalloprotease activity does not occur. Other readily assayable cellular changes can be used to tnonher this result, including gene expression, changes in mitotic activity, and the like. Example 10 A small molecular weight metalloprotease inhibitor is used to treat a tissue culture according to the method of Example 7. The release of TNF-a from the cell membrane is measured by literature methods. The inhibitor of Example 7 also decreases the amount of TNF-a secreted from the cell membrane. This is consistant with the theory that inhibition of disintegrin metalloprotease activity will result in the inhibition of a disintegrin associated inflammation cascade and Printed from Mimosa WO 97/31931 11 PCIYUS97/03217 33 1844 secretase activity. It is contemplated that monitoring the release of cytokines or EL-1 from the cell membrane, and the like will produce the same result. All references described herein are hereby incorporated by reference. While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the art that various changes and modifications of the subject invention can be made without departing from the scope of the invention as defined by the appended claims. intellectual propwty office of ni. - t MAY 2000 RECEIVED WO 97/31931 PCT/US97/03217 12 SEQUENCE LISTING (1) GENERAL INFORMATION: |i) APPLICANT: TINDAL, MICHAEL H. HAQQI, TARIQ M. (ii) TITLE OF INVENTION! USE OF A NOVEL DISINTEGRIN METALLOPROTEASi:, ITS MUTANTS, FRAGMENTS AND THE LIKE Uii) NUMBER OF SEQUENCES: 4 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: THE PROCTER £ GAMBLE COMPANY (B) STREET: 0700 MASON-MONTGOMERY ROAD <C) CITY: MASON (D) STATE: OHIO (E) COUNTRY: USA (F) ZIP: 45040-9462 (v) COMPUTER READABLE FORM: <A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFMARE: Patentln Release #1.0, Version #1.30 (Vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US 60/012,679 (B) FILING DATE: 01-MAR-1996 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: HAKE, RICHARD A. (B) REGISTRATION NUMBER: 37,343 (C) REFERENCE/DOCKET NUMBER: 5980 lix) TELECOMflJtiICATION INFORMATION: (A) TELEPHONE: 513/622-0087 (B) TELEFAX: 513/622-0270 (2) INFORMATION FOR SEQ ID NO: Is (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1961 base pairs (B) TYPE: nucleic acid (C> STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..1474 (Xi) SEQUENCE: DESCRIPTION: SEQ ID NOil: Printed frorr. Mimosa WO 97/31931 PCT/US97/03217 13 C CAG ACC ACA GAC TTC TCC GGA ATC CGT AAC ATC AGT TTC ATG GTG 46 Gin Tht Thr Asp Phe Sar Gly lie Arg Asn He Ser Phe Met Val 15 10 15 AAA CGC ATA AGA ATC AAT ACA ACT GCT GAT GAG AAG GAC CCT ACA AAT 94 Lys Arg lie Arg lie Asn Thr Thr Ala Asp Glu Lys Asp Pro Thr Asn 20 25 30 CCT TTC CGT TTC CCA AAT ATT AGT GTG CiAG AAG TTT CTG GAA TTG AAT 142 Pro Phe Arg Phe Pro Asn lie Ser Val Glu Lvs Phe Leu Glu Leu Asn 35 40 45 TCT GAG CA(i AAT CAT GAT GAC TAC TGT TTG GCC TAT GTC TTC ACA GAC 190 Ser Glu Gin Asn His Asp Asp Tyr Cys Leu Ala Tyr Val Phe Thr Asp 50 55 60 CGA GAT TTT GAT GAT GGC GTA CTT GGT CTG GCT TGG GTT GGA GCA CCT 238 Arg Asp Phe Asp Asp Gly Val Leu Gly Leu Ala Trp Val Gly Ala Pro 65 70 75 TCA GGA AGC TCT GGA GGA ATA TGT GAA AAA AGT AAA CTC TAT TCA GAT 286 Ser Gly Ser Ser Gly Gly lie Cys Glu Lys Ser Lys Leu Tyr Ser Asp 80 85 90 95 GGT AAG AAG AAG TCC TTA AAC ACT GGA ATT ATT ACT GTT CAG AAC TAT 334 Gly Lys Lys Lys Sar Leu Asn Thr Gly lie lie Thr Val Gin Asn Tyr 100 105 110 GGG TCT CAT GTA CCT CCC AAA GTC TCT CAC ATT ACT TTT GCT CAC GAA 382 Gly Sar His Val Pro Pro Lya Val Ser His He Thr Phe Ala His Glu 115 120 125 GTT GGA CAT AAC TTT GGA TCC CCA CAT GAT TCT GGA ACA GAG TGC ACA 430 Val Gly Hi* Asn Phe Gly Sar Pro His Asp s«r Gly Thr Glu Cys Thr 130 135 140 CCA GGA GAA TCT AAG AAT TTG GGT CAA AAA GAA AAT GGC AAT TAC ATC 478 Pro Gly Glu Sar Lys Asn Leu Gly Gin Lys Glu Asn Gly Asn Tyr lie 145 150 155 ATG TAT GCA AGA GGA AC TCT GGG GAC AAA CTT AAC AAC AAT AAA TTC 526 Mat Tyr Ala Arg Ala Thr Sar Gly Asp Lys L«u Asn Asn Asn Lys Pha 160 165 170 175 TCA CTC TGT AGT ATT AGA AAT ATA AGC CAA GTT CTT GAS AAG AAG AGA 574 Sar Lau Cys Scr 11a Arg Asn 11a Sar G.ln Val Leu Glu Lys Lys Arg 180 185 190 AAC AAC TGT TTT GTT GAA TCT GGC CAA CCT ATT TGT GGA AAT GGA ATG 622 Asn Asn cys Pha Val Glu Sar Gly Gin Pro Ila Cya Gly Asa Gly Met 195 200 205 GTA GAA CAA GGT GAA GAA TGT GAT TGT GGC TAT AGT GAC CAS TGT AAA 670 Val Glu Gin Gly Glu Glu Cys Asp Cys Gly Tyc Sar Asp Gin Cys Lys 210 215 220 GAT GAA TGC TGC TTC GAT GCA AAT CAA CCA GAG GGA AGA AAA TGC AAA 718 Asp Glu Cys Cys Pha Asp Ala Asn Gin Pro Glu Gly Arg Lys Cys Lys Printed from Mimosa WO 97/31931 PCT/US97/03217 14 225 230 235 CTG AAA CCT GGG AAA CAG TGC AGT CCA AGT CAA GGT CCT TGT TGT ACA 766 Leu Lya Pro Gly Lya Gin Cya 3er Pro Ser Gin Gly Pro Cya Cys Thr 240 245 250 255 GCA CAG TGT GCA TTC AAG TCA AAG TCT GAG AAG TGT CGG GAT GAT TCA 014 Ala Gin Cya Ala Phe Lys Ser Lya Ser Glu Lya Cya Arg Aap Asp "er 260 265 270 GAC TGT GCA AGG GAA GGA ATA TGT AAT GGC TTC ACA GCT CTC TGC CCA 662 Aap Cya Ala Arg Glu Gly He Cya Aan Gly Phe Thr Ala Leu Cya Pro 275 200 285 GCA TCT GAC CCT AAA CCA AAC TTC ACA GAC TGT AAT AGG CAT ACA CAA 910 Ala Ser Aap Pro Lya Pro Asn Phe Thr Asp Cya Aan Arg His Thr Gin 290 295 300 GTG TGC ATT AAT GGG CAA TGT GCA GGT TCT ATC TGT GAG AAA TAT GGC 950 Val Cya lie Aan Gly Gin Cys Ala Gly Ser lie Cys Glu Lys Tyr Gly 305 310 315 TTA GAG GAG TGT ACG TGT GCC AGT TCT GAT GGC AAA GAT GAT AAA GAA 1006 Leu Glu Glu Cya Thr Cya Ala Sar Sar Asp Gly Lys Asp Asp Lya Glu 320 32S 330 335 TTA TGC CAT GTA TGC TGT ATG AAG AAA ATG GAC CCA TCA ACT TGT GCC 1054 Leu Cys His Val Cys Cys Met Lys Lys Met Asp Pro Ser Thr Cys Ala 340 345 350 AGT ArJ~ o>TG TCT GTG CAG TGG AGT AGG CAC TTC AGT GGT CGA ACC ATC 1102 Ser li-s cly Ser Val Gin Trp Ser Arg His Phe Sar Gly Arg Thr lie 355 360 365 ACC CTG CAA CCT GGA TCC CCT TGC AAC GAT TTT AGA GGT TAC TGT GAT 1150 Thr Leu Gin Pro Gly Ser Pro Cys Asn Asp Phe Arg Gly Tyc Cys Asp 370 375 360 GTT TTC ATG CGG TGC AGA TTA GTA GAT GCT GAT GGT CCT CTA GCT AGG 1190 Val Phe Met Arg Cys Arg Leu Val Asp Ala Asp Gly Pro Leu Ala Arg 305 390 395 CTT AAA AAA GCA ATT TTT AGT CCA GAG CTC TAT GAA AAC ATT GCT GAA 1246 Leu Lys Lys Ala lie Phe Ser Pro Glu Leu Tyr Glu Asn lie Ala Glu 400 405 410 415 TGG ATT GTG GCT CAT TGG TGG GCA GTA TTA CTT ATG GGA ATT GCT CTG 1294 Trp XI* Val Ala His Trp Trp Ala Val Leu Leu Met Gly II* Al* Leu 420 42S 430 ATC ATG CTA ATG GCT GGA TTT ATT AAG ATA TGC AGT GTT CAT ACT CCA 1342 11* Met L*u Met Sly Phe 11* Lys XI* Cys S*r Val His Thr Pro 435 440 445 AGT AGT AAT CCA AAG TTG CCT CCT CCT AAA CCA CTT CCA GGC ACT TTA 1390 S*r Ser Asn Pro Lys Leu Pro Pro Pro Lys Pro Leu Pro Gly Thr Leu 450 45S 460 AAG AGG AGG AGA CCT CCA CAG CCC ATT CAG CAA CCC CAG CGT CAS CGG 1430 Printed from Mimosa WO 97/31931 PCT/US97/03217 15 Lya Arg Arg Arg Pro Pro Gin Pro II* Gin Gin Pro Gin Arg Gin Arg 465 470 475 CCC CGA GAG AGT TAT CAA ATG GGA CAC ATG AGA CGC TAACTGCAGC 1484 Pro Arg Glu Ser Tyr Gin Met Gly Hia Met Arg Arg 480 485 490 TTTTGCCTTG GTTCTTCCTA GTGCCTACAA TGGGAAAACT TCACTCCAAA GAGAAACCTA 1544 TTAAGTCATC ATCTCCAAAC TAAACCCTCA CAAGTAACAG TTGAAGAAAA AATGGCAAGA 1604 GATCAT ATCC TCAGACCAGG TGGAATTACT TAAATTTTAA AGCCTGAAAA TTCCAATTTG 1664 GGGGTGGGAG GTGGAAAAGG AACCCAATTT TCTTATGAAC AGATATTTTT AACTTAATGG 1724 CACAAAGTCT TAGAATATTA TTATGTGCCC CGTGTTCCCT GTTCTTCGTT GCTGCATTTT 1784 CTTCACTTGC AGGCAAACTT GGCTCTCAAT AAACTTTTCG GTCCAGACCA CAGACTTCTC 1844 CGGAATCCGT AACATCAGTT TCATGGTGAA ACGCATAAGA ATCAATACAA CTGCTGATGA 1904 GAAGGACCCT ACAAATCCTT TCCGTTTCCC AAATATTAGT GTGGAGAAGT TAAACAA 1961 (2) INFORMATION FOR SEQ ID NO:2: (1) SEQUENCE CHARACTERISTICS; (A) LENGTH: 491 amino ados IB) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Gin Thr Thr Aap Phe Sar Gly II* Arg Aan lie Ser Phe Met Val Lys 15 10 15 Arg Ila Arg lie Asn Thr Thr Ala Asp Glu Lys Asp czo Thr Asn Pro 20 25 30 Phe Arg Phe Pro Asn Ila Sar Val Glu I.ya Phe Leu Glu Leu Asn Sar 35 40 45 Glu Gin Asn His Asp Asp Tyr Cys Leu Ala Tyr Val Phe Thr Asp Arg 50 55 60 Asp Ph* Asp Asp Gly Val Leu Gly Leu Ala Trp Val Gly Ala Pro Ser 65 70 75 80 Gly S«r S*r Gly Gly II* Cys Glu Lys Sar Lys Leu Tyr S*r Asp Gly 85 90 95 Lys Lys Lys Ser Leu Asn Thr Gly II* II* Thr Val Gin Asn Tyr Gly 100 105 110 Sar His Val Pro Pro Lya Val Sar His Ila Thr Pha Ala His Glu Val 115 120 125 Printed from Mimosa WO 97/31931 16 PCT/US97/03217 Gly His Aan Phe Gly Ser Pro His Aap Ser Gly Thr Glu Cya Tiir Pro 130 135 140 Gly Glu S«r Lys Asn Leu Gly Gin Lys Glu Aan Gly Aan Tyr lie Met 145 150 155 160 Tyr Ala Arg Ala Thr Ser Gly Aap Lys Leu Asn Aar. Aan Lys Phe Ser 165 170 175 Leu Cys Ser lie Arg Asn lie Ser Gin Val Leu Glu Lys Lys Arg Asn ISO 165 190 Asn Cys Phe Vel Glu Ser Gly Gin Pro II* Cys Gly Asn Gly Met Val 195 200 205 Glu Gin Gly Glu Glu Cys Asp Cya Gly Tyr Ser Aap Gin Cya Lys Asp 210 215 220 Glu Cys Cys Phe Asp Ala Asn Gin Pro Glu Gly Arg Lys Cys Lys Leu 225 230 235 240 Lys Pro Gly Lys Gin Cys Ser Pro Ser Gin Gly Pro Cys Cys Thr Ala 245 250 255 Gin Cys Ala Phe Lys Sar Lys Sar Glu Lys Cys Arg Asp Asp Ser Asp 260 265 270 Cys Ala Axg Glu Gly He Cya Asn Gly Phe Thr Ala Leu Cya Pro Ala 275 280 205 Ser Aiip Pro Lys Pro Asn Pha Thr Asp Cya Aan Arg His Thr Gin Val 290 295 300 Cys lie Asn Gly Gin Cys Ala Gly Ser lie Cys Glu Lys Tyr Gly Leu 305 310 315 320 Glu Glu Cys Thr Cys Ala Ser 5«r Asp Gly Lys Asp Asp Lys Glu Lau 325 330 335 Cys His Val Cys Cys Mat Lya Lys Met Aap Pro Ser Thr Cys Ala Ser 340 345 350 Thr Gly Ser Val Gin Trp Ser Arg His Pha Sar Gly Arg Thr Ila Thr 3S5 360 365 Lau Gin Pro Gly Ser Pro Cys Asn Asp Pha Arg Gly Tyr Cys Asp Val 370 375 360 Pha Mat Arg Cys Arg Lau Val Asp Ala Aap Gly Pro Leu Ala Arg Lau 365 390 395 400 Lys Lys Ala Zla Pha Sar Pro Glu Lau Tyr Glu Asn lie Ala Glu Trp 405 410 415 He Val Ala His Trp Trp Ala Val Leu Leu Met Gly Ila Ala Lau lie 420 425 430 Met Leu Met Ala Gly Phe Zle Lya He Cys Ser Val Kis Thr Pro Ser 435 440 445 Printed from Mimosa WO 97/31931 PCT/US97/03217 17 Ser Aan Pro Lys Leu Pro Pro Pro Lys Pro Leu Pro Gly Thr Leu Lys 450 455 460 Arg Arg Arg Pro Pro Sin Pro lie Gin Gin Pro Gin Arg Gin Arg Pro 465 470 475 4 BO Arg Glu Ser Tyr Gin Met Gly His Met Arg Arg 465 490 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2763 base pairs IB) TYPE: nucleic acid (C) STRAHDEDNESS: single (D> TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) <ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 17..2414 (Xi) SEQUENCE DESCRIPTION: SEQ ID NOi3: GGCGGCGGCA CGGAAG ATG GTG TTG CTG AGA GTG TTA ATT CTG CTC CTC 49 Mat Val Lau Leu Arg Val Lau lie Lau Lau Leu 495 500 TCC TGG GCG GCG GGG ATG GGA GGT CAG TAT GGG AAT CCT TTA AAT AAA 97 Sar Trp Ala Ala Gly Met Gly Gly Gin Tyr Gly Asn Pro Lau Asn Lys 505 510 515 TAT ATC AGA CAT TAT W. GGA TTA TCT TAC AAT GTG GAT TCA TTA CAC 145 Tyr lie Arg His Tyr Glu Gly Lau Ser Tyr Asn Val Asp Sar Leu Hia 520 525 530 CAA AAA CAC CAG CCT GCC AAA AGA GCA GTC TCA CAT GAA GAC CAA TTT 193 Gin Lys His Gin Arg Ala Lys Arg Ala Val Ser His Glu Asp Gin Phe 535 540 545 550 TTA CGT CTA CAT TTC CAT GCC CAT GGA AGA CAT TTC AAC CTA CGA ATG 241 Leu Arg Lau Asp Phe His Ala His Gly Arg His Phe Asn Lau Arg Met 555 560 565 AAG AGG GAC ACT TCC CTT TTC ACT GAT GAA TTT AAA GTA GAA ACA TCA 289 Lys Azg Aap Thr Ser Leu Pha Ser Asp Glu Pha Lys Val Glu Thr Ser 570 575 580 AAT AAA CTA CTT GAT TAT GAT ACC TCT CAT AIT TAC ACT GCA CAT ATT 337 Asn Lys Val Lau Asp Tyr Asp Thr Sar His lie Tyr The Gly His lie 585 59f 595 TAT CGT GAA GAA CGA AGT TTT A& CAT GGG TCT GTT ATT GAT GGA AGA 385 Tyr Gly Glu Glu Gly Sar Phe Ser His Gly Sar Val lie Asp Gly Arg 600 60S 610 Printed from Mimosa WO 97/31931 PCT/US97/03217 18 TTT GAA GGA TTC ATC CAG ACT CGT GGT GGC ACA TTT TAT GTT GAG CCA 433 Phe Glu Gly Phe tie Gin Thr Arg Gly Gly Thr Phe Tyr Val Glu Pro 615 620 625 630 GCA GAG AGA TAT ATT AAA GAC CGA ACT CTG CCA TTT CAC TCT GTC ATT 401 Ala Glu Arg Tyr lie Lys Aap Arg Thr Leu Pro Phe His Ser Val lie 635 640 645 TAT CAT GAA GAT GAT ATT AGT GAA AGG CTT AAA CTG AGG CTT AGA AAA 529 Tyr His Glu Asp Asp lie Ser Glu Arg Leu Lys Lau Arg Leu Arg Lys 650 655 660 CTT ATG TCA CTT GAG TTG TGG ACC TCC TGT TGT TTA CCC TGT GCT CTT 577 Leu Met Ser Lau Glu Lau Trp Thr Ser Cys Cys Leu Pro Cys Ala Leu 665 670 675 CTG CTT CAC TCA TGG AAG AAA GCT GTA AAT TCT CAC TGC CTT TAC TTC 625 Leu Leu His Sar Trp Lys Lya Ala Val Aan Ser Hia Cya Lau Tyr Phe 680 685 690 AAG GAT TTC TGG GGC TTT TCT GAA ATC TAC TAT CCC CAT AAA TAC GGT 673 Lys Aap Phe Trp Gly Phe Ser Glu lie Tyr Tyr Pro His Lys Tyr Gly 695 700 705 710 CCT CAG GGC GGC TGT GCA GAT CAT TCA GTA TTT GAA AGA ATG AGG AAA 721 Pro Gin Gly Gly Cys Ala Aap His Ser Val Phe Glu Arg Mat Arg Lya 715 720 725 TAC CAG ATG ACT GGT GTA GAG GAA GTA ACA CAG ATA CCT CAA GAA GAA 769 Tyr Gin Met Thr Gly Val Glu Glu Val Thr Gin lie Pro Gin Glu Glu 730 735 740 CAT GCT GCT AAT GGT CCA SAA CTT CTG AGG AAA AGA CGT ACA ACT TCA 817 His Ala Ala Asn Gly Pro Glu Lau Leu Arg Lys Arg Arg Thr Thr Ser 745 750 755 GCT GAA AAA AAT ACT TGT CAG CTT TAT ATT CAG ACT GAT CAT TTG TTC 865 Ala Glu Lys Asn Thr Cys Gin Lau Tyr lie Gin Thr Asp His Leu Phe 760 765 770 TTT AAA TAT TAC GGA ACA CGA GAA GCT GTG ATT GCC CAG ATA TCC AGT 913 Pha Lya Tyr Tyr Gly Thr Arg Glu Ala Val Ila Ala Gin Ila Sar Sar 775 780 7S5 790 CAT GTT AAA GCG ATT GAT ACA ATT TAC CAG ACC ACA GAC TTC TCC GGA 961 His Val Lys Ala He Asp Thr lie Tyr Gin Thr Thr Aap Phe Ser Gly 795 800 805 ATC CGT AAC ATC AGT TTC ATG GTG AAA CGC ATA AGA ATC AAT ACA ACT 1009 lie Arg Asn Ila Sac Pha Met Val Lys Arg Ila Arg Ila Asn Thr Thr 810 815 820 GCT GAT (SAG AAG GAC CCT ACA AAT CCT TTC CGT TTC CCA AAT ATT AGT 1057 Ala Asp Glu Lys Asp Pro Tht Asn Pro Pha Arg Phe Pro Asn Ila Sar 825 830 835 GTG GAG AAG TTT CTG GAA TTG AAT TCT GAG CAG fAT CAT GAT GAC TAC 1105 Val Glu Lys Pha Lau Glu Lau Asn Sar Glu Gin Asn His Asp Asp Tyr Printed from Mimosa WO 97/31931 PCT/US97/03217 19 840 845 850 TGT Cys 855 TTG Leu GCC Ala TAT Tyr GTC Val TTC Phe B60 ACA Thr GAC Asp CGA Arg GAT Asp TTT GAT Phe Asp 665 GAT Asp GGC GTA Gly Val CTT Leu 670 1153 GGT Gly CTG Lau GCT Ala TGG Trp GTT Val 875 GGA Gly GCA Ala CCT Pro TCA Ser GGA Gly 880 AGC Ser TCT Ser GGA. Gly GGA Gly ATA lie 885 TGT Cys 1201 GAA Glu AAA Lys AGT Sec AAA Lys 890 CTC Lau TAT Tyr TCA Ser GAT Asp GGT Gly 895 AAG Lys AAG Lys AAG Lys TCC Ser TTA Leu 900 AAC Asn ACT Thr 1249 GGA Gly ATT lie ATT lie 90S ACT Thr GTT Val CAG Gin AAC Aan TAT Tyr 910 GGG Gly TCT Ser CAT His GTA Val CCT Pro 915 CCC Pro AAA Lya GTC Val 1297 TCT Ser CAC His 920 ATT He ACT Thr TTT Phe GCT Ala CAC Kis 925 GAA Glu GTT Val GGA CAT Gly His AAC Asn 930 TTT Phe GGA Gly TCC Ser CCA Pro 1345 CAT His 935 GAT Asp TCT Ser GGA ACA Gly Thr GAG Glu 940 TGC Cys ACA Thr CCA Pro GGA GAA Gly Glu 945 TCT Sar AAG Lys AAT Asn TTG Leu GGT Gly 950 1393 CAA Gin AAA Lys GAA Glu AAT Asn GGC Gly 955 AAT Asn TAC Tyr ATC lie ATG Met TAT GCA AGA Tyr Ala Arg 960 GCA Ala ACA The TCT Sar 965 GGG Gly 1441 GAC Aap AAA Lys CTT Leu AAC Asn 970 AAC Asn AAT Asn AAA Lys TTC Phe TCA Ser 975 CTC Leu TGT Cys AGT Sar ATT AGA AAT lie Arg Asn 980 ATA He 1489 AGC Sec CAA Gin GTT Val 98S CTT Leu GAG Glu AAG Ly» AAG Lys AGA Arg 990 AAC Asn AAC Asn TGT Cys TTT Phe GTT Val 99S GAA Glu TCT Sar GGC Gly 1537 CAA Gin ccr ATT Pco Ila 1000 TGT Cys GGA Gly AAT Asn GGA ATG Gly Met 1005 GTA Val GAA CAA GGT GAA Glu Gin Gly Glu 1010 GAA Glu TGT Cys GAT Asp 1585 TCT GGC Cya Gly 1015 TAT Tyr AGT GAC Sac Asp CAG TGT Gin Cya 1020 AAA Lys GAT Aap GAA Glu TGC TGC Cys Cys 1025 TTC GAT GCA Pha Asp Ala AAT Asn 1030 1633 CAA Gin CCA Pro GAG Glu GGA Gly AGA AAA Arg Lys 1035 TGC Cys AAA Lys CTG Lau AAA CCT Lys Pro 1040 GGG Gly AAA Lys CAG Gin TGC AGT Cys Sar 1045 1681 CCA Pro AGT Ser CAA Gin GGT CCT TGT Gly Pro cys 1050 TGT Cys ACA Thr GCA CAG Ala Gin 1055 TGT GCA Cys Ala TTC Pha AAG TCA Lys Sar 1060 AAG Lys 1729 TCT Sac GAG Glu AAG TGT Lys Cys 1065 CGS GAT Arg Asp GAT Asp TCA GAC Sar Asp 1070 TGT Cys GCA AGG Ala Arg GAA GGA Glu Gly 1075 ATA lie TGT Cys 1777 AAT GGC TTC ACA GCT CTC TrSC CCA GCA TCT GAC CCT AAA CCA AAC TTC 1825 Printed from Mimosa WO 97/31931 PCT/US97/03217 20 Aan Gly Phe Thr Ala Leu Cya Pro Ala Ser Aap Pro Lys Pro Asn Phe 1000 1065 1090 ACA GAC TGT AAT AGG CAT ACA CAA GTG TGC ATT AAT GGG CAA TGT GCA 1873 Thr Aap Cya Aan Arg His Thr Gin Val Cys lie Asn Gly Gin Cya Ala 1095 1100 1105 1110 GGT TCT ATC TGT GAG AAA TAT GGC TTA GAG GAG TGT ACG TGT GCC AGT 1921 Gly Ser lie Cya Glu Lya Tyr Gly Leu Glu Glu Cya Thr Cys Ala Ser 1115 1120 1125 TCT GAT GGC AAA GAT GAT AAA GAA TTA TGC CAT GTA TGC TGT ATG AAG 1969 Ser Asp Gly Lys Asp Asp Lya Glu Leu Cys His Val Cys Cys Met Lys 1130 1135 1140 AAA ATG GAC CCA TCA ACT TGT GCC AGT ACA GGG TCT GTG CAG TGG AGT 2017 Lys Met Asp Pro Ser Thr Cys Ala Ser Thr Gly Ser Val Gin Trp Ser 1145 1150 1155 AGG CAC TTC AGT GGT CGA ACC ATC ACC CTG CAA CCT GGA TCC CCT TGC 2065 Arg His Phe Ser Gly Arg Thr lie Thr Leu Gin Pro Gly Ser Pro Cys 1160 1165 1170 AAC GAT TTT AGA GGT TAC TGT GAT GTT TTC ATG CGG TGC AGA TTA GTA 2113 Asn Asp Phe Arg Gly Tyr Cys Asp Val Phe Met Arg Cys Arg Leu Val 1175 1160 1165 1190 GAT GCT GAT GGT CCT CTA GCT AGG CTT AAA AAA GCA ATT TTT AGT CCA 2161 Asp Ala Asp Gly Pro Leu Al* Arg Lau Lya Lys Ala lie Phe Ser Pro 1195 1200 1205 GAG CTC TAT GAA AAC ATT GCT GAA TGG ATT GTG GCT CAT TGG TGG GCA 2209 Glu Leu Tyr Glu Asn lie Ala Glu Trp lie Val Ala His Trp Trp Ala 1210 1215 1220 GTA TTA CTT ATG GGA ATT GCT CTG ATC ATG CTA ATG GCT GGA TTT ATT 2257 Val Leu Leu Mat Gly He Ala Lau He Mat Leu Mat Ala Gly Phe lie 1225 1230 1235 AAG ATA TGC AGT GTT CAT ACT CCA AGT AGT AAT CCA AAG TTG CCT CCT 2305 Lys lie Cys Sar Val His Thr Pro Ser Ser Asn Pro Lys Leu Pro Pro 1240 1245 1250 CCT AAA CCA CTT CCA GGC ACT TTA AAG AGG AGG AOA CCT CCA CAG CCC 2353 Pro Lys Pro Leu Pro Gly Thr Leu Lys Arg Arg Arg Pro Pro Gin Pro 1255 1260 1265 1270 ATT CAG CAA CCC CAG CGT CAG CGC CCC CGA GAG AGT TAT CAA ATG GGA 2401 Ila Gin Gin Pro Gin Arg Gin Arg Pro Arg Glu Sar Tyr Gin Mat Gly 1275 1280 1285 CAC ATG AGA CGC T AACTGCAGCT TTTGCCTTGG TTCTTCCTAG TGCCTACAAT 2454 His Met Arg Arg 1290 GGGAAA>»CTT CACTCCAAAG AGAAACCTAT TAAGTCATCA TCTCCAAACT AAACCCTCAC 2514 AAGTAACilGT TGAAGAAAAA ATGGCAAGAG ATCATATCCT CAGACCAGGT GGAATTACTT 2574 Printed from Mimosa WO 97/31931 PCT/US97/03217 21 AAATTTTAAA GCCTGAAAAT TCCAATTTGG GGGTGGGAGG TGGAAAAGGA ACCCAATTTT 2634 CTTATGAACA GATATTTTTA ACTTAATGGC ACAAAGTCTT AGAATATTAT TATGTGCCCC 2694 GTGTTCCCTG TTCTTCGTTG CTGCATTTTC TTCACTTGCA GGCAAACTTG GCTCTCAATA 27S4 AACTTTTCG 2763 (2) INFORMATION FOR SEQ ID NO:4: Ii) SEQUENCE CHARACTERISTICS: (A) LENGTH: 799 amino acida (B) TYPE: amino acid (D) TOPOLOGY: iinaar (ii) MOLECULE TYPE: protain (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Val Leu Leu Arg Val Leu lie Lau Lau Leu Ser Trp Ala Ala Gly IS 10 15 Met Gly Gly Gin Tyr Gly Aan Pro Leu Aan Lys Tyr Ila Arg Hia Tyr 20 2S 30 Glu Gly Leu Ser Tyr Aan Val Asp Sar Lau Hit Gin Lys Hia Gin Arg 35 40 45 Ala Lys Arg Ala Val Ser His Glu Asp Gin Phe Lau Arg Leu Aap Pha 50 55 60 Hia Ala His Gly Arg Hia Phe Aan Leu Arg Met Lys Arg Asp Thr Ser 65 70 75 80 Leu Phe Ser Aap Glu Pha Lys Val Glu Thr Ser Asn Lys Val Lau Asp 85 90 95 Tyr Aap Thr Ser His lie Tyr Thr Gly His lie Tyr Gly Glu Glu Gly 100 105 110 Ser Phe Ser His Gly Sar Val lie Aap Gly Arg Phe Glu Gly Phe lie 115 120 125 Gin Thr Arg Gly Gly The Phe Tyr Val Glu Pro Ala Glu Arg Tyr Zla 130 135 140 Lys Asp Arg Thr Leu Pro Phe Hia Sar Val lie Tyr His Glu Aap Asp 145 150 155 160 lie Ser Glu Arg Leu Lys Leu Arg Leu Arg Lys Leu Met Sar Leu Glu 165 170 175 Leu Trp Thr Ser Cys Cya Leu Pro Cys Ala Leu Leu Leu His Sar Trp 180 185 190 Lys Ly,» Ala Val Asn Ser Hia Cys Lau Tyr Phe Lys Asp Phe Trp Gly 1»5 200 205 Printed from Mimosa WO 97/31931 22 PCT/US97/03217 Phe Ser Glu lie Tyr Tyr Pro His Lys Tyr Gly Pro Gin Gly Gly Cys 210 215 220 Ala Asp His Ser Val Phe Glu Arg Het Arg Lys Tyr Gin Met Thr Gly 225 230 235 240 Val Glu Glu Val Thr Gin lie Pro Gin Glu Glu His Ala Ala Asn Gly 245 25C 255 Pro Glu Leu Leu Arg Lys Arg Arg Thr Thr Ser Ala Glu Lys Asn Thr 260 265 270 Cys Gin Leu Tyr lie Gin Thr Asp His Leu Phe Phe Lys Tyr Tyr Gly 275 280 265 Thr Arg Glu Ala Val He Ala Gin He Ser Ser His Val Lys Ala He 290 295 300 Asp Thr Ila Tyr Gin Thr Thr Asp Phe Ser Gly lie Arg Asn Ila Ser 305 310 315 320 Phe Met Val Lys Arg lie Arg lie Asn Thr Thr Ala Asp Glu Lys Asp 325 330 335 Pro Thr Asn Pro Phe Arg Pha Pro Asn 11* Ser Val Glu Lys Phe Leu 340 345 350 Glu Lau Asn Sar Glu Gin Asn His Asp Asp Tyr Cys Leu Ala Tyr Val 355 360 365 Phe Thr Asp Arg Asp Phe Asp Asp Gly Val Leu Gly Leu Ala Trp Val 370 375 Gly Ala Pro Ser Gly Ser Ser Gly Gly He Cys Glu Lys Ser Lys Leu 365 390 395 400 Tyr Ser Asp Gly Lys Lys Lys Ser Leu Asn Thr Gly He lie Thr Val 405 410 415 Gin Asn Tyr Gly Ser His Val Pro Pro Lys Val Ser His lie Thr Phe 420 425 430 Ala His Glu Val Gly His Asn Phe Gly Ser Pro His Asp Ser Gly Thr 435 440 445 Glu Cys Thr Pro Gly Glu Ser Lys Asn Leu Gly Gin Lys Glu Asn Gly 450 455 460 Asn Tyr lie Met Tyr Ala Arg Ala Thr Sar Gly Asp Lys Leu Asn Asn 465 470 475 480 Asn Lys Phe Ser Leu Cys Ser lie Arg Asn lie Ser Gin Val Leu Glu 485 490 495 Lys Lys Arg Asn Asn Cys Phe Val Glu Ser Gly GJ n Pro lie Cys Gly 500 505 510 Asn Gly Met Val Glu Gin Gly Glu Glu Cys Asp Cys Gly Tyc Ser Aap 515 520 325 Printed from Mimosa </div>

Claims

<div class="application article clearfix printTableText" id="claims"> WO 97/31931 PCT/US97/03I17 23 Gin Cys Lys Asp Glu Cys Cys Phe Asp Ala Asn Gin Pro Glu Gly Arg 530 535 540 Lys Cys Lys Leu Lys Pro Gly Lys Gin Cys Ser Pro Ser Gin Gly Pro 545 550 555 560 Cys Cys Thr Ala Gin Cys Ala Phe Lys Ser Lys Ser Glu Lys Cys Arg 565 570 575 Asp Asp Ser Asp Cys Ala Arg Slu Gly lie Cys Asn Gly Phe The Ala 580 585 590 Leu Cys Pro Ala ser Asp Pro Lys Pro Asn Phe Thr Asp cys Asn Arg 595 600 605 His Thr Gin Val Cys lie Aan Gly Gin Cys Ala Gly Ser lie Cys Glu 610 615 620 Lys Tyr Gly Leu Glu Glu Cys Thr Cys Ala Ser Ser Asp Gly Lys Asp 625 630 635 640 Aap Lys Glu Leu Cys His Val Cya Cys Met Lys Lys Met Aap Pro Ser 645 650 655 Thr Cys Ala Ser Thr Gly Ser Val Gin Trp Ser Arg His Phe Ser Gly 660 665 670 Arg Thr lie Thr Leu Gin Pro Gly Ser Pro Cys Asn Aap Phe Arg Gly 675 680 685 Tyr Cys Asp Val Phe Met Arg Cys Arg Leu Val Asp Ala Asp Gly Pro 690 695 700 Leu Ala Arg Leu Lys Lys Ala lie Phe Ser Pro Glu Leu Tyr Glu Asn 705 710 715 720 lie Ala Glu Trp lie Val Ala His Trp Trp Ala Val Leu Leu Met Gly 725 730 735 lie Ala Leu lie Met Leu Met Ala Gly Phe lie Lyi lie Cys Ser Val 740 745 750 Hia: Thr Pro Ser Sec Asn Pro Lys Leu Pro Pro Pro L, i Pro Leu Pro 755 760 765 Gly Thr Leu Lys Arg Arg g Pro Pro Gin Pro He Gin Gin Pro Gin 770 7B0 Arg Gin Arg Pro Azg Glu Sex Tyr Gin Met Gly Hia Met Arg Arg 785 790 795 Printed from Mimosa -W , Qgf 24 WHAT IS CLAIMED IS: 1.
An isolated nucleic acid comprising a nucleotide sequence encoding the human disintegrin of SEQ ID NO:4 or a functionally equivalent fragment thereof. 2.
A human disintegrin comprising an amino acid sequence which is the amino acid sequence as set forth in SEQ ID NO:4, or a functionally equivalent fragment thereof, in essentially pure form. 3.
A screening method for compounds capable of inhibiting the human disintegrin of Claim 2 comprising: A) exposing a sample containing disintegrin to a candidate compound or control compound; B) determining the level of disintegrin activity in each sample; and C) comparing the effect of the candidate compound on the disintegrin activity within the control. 4.
An antibody, or a functionally equivalent fragment thereof to the human distintegrin of Claim 2. 5.
A screening method for a metalloprotease medicated disease comprising: A) providing a test sample; and B) determining the level of disintegrin present in the test sample using an antibody of Claim 4. 6.
A screening method for osteoarthritis comprising: A) providing a test sample; and B) determining the level of disintegrin present in the test sample using an antibody of Claim 4. intellectual property office of n.z. -t MAY 2000 RECEIVED 25
8. A screening kit for osteoarthritis comprising the antibody of Claim 4.
9. The screening method according to Claim 3 wherein the level of disintegrin activity is determined using a fluorogenic peptide substrate.
10. The nucleic acid of Claim 1 which comprises the sequence set forth in SEQ ED NO:3.
11. An expression vector or plasmid comprising the nucleic acid of Claim 10.
12. A cell comprising the expression vector or plasmid of Claim 11.
13. The cell of Claim 12 where the DNA is foreign to that cell.
14. An inhibitor of the human disintegrin of Claim 1 or 2.
15. The use of the inhibitor of Claim 14 in the manufacture of a medicament for treating a disease state associated with disintegrin activity.
16. The use of an inhibitor in the manufacture of a medicament for treating a disease state associated with disintegrin activity wherein the inhibitor is an antibody, or fragment thereof, to the human disintegrin of Claim 2.
17. A use as claimed in Claim 15 or 16 wherein the disease is an arthropothy.
18. A use according to Claim 17, wherein the disease is osteoarthritis.
19. An isolated nucleic acid according to Claim 1 and substantially as herein described with reference to any embodiment disclosed.
20. A human disintegrin according to Claim 2 and substantially as herein described with INTELLECTUAL PROPERTY OFFICE 0FN7. 10 APR 2000 RECEIVED ?? in/ U \J \ Ii ii /? 26 reference to any embodiment disclosed.
21. A screening method according to any one of Claims 3, 5, and 6 and substantially as herein described with reference to any embodiment disclosed.
22. A screening kit according to Claim 8 and substantially as herein described with reference to any embodiment disclosed.
23. An antibody, or fragment thereof, according to Claim 4 and substantially as herein described with reference to any embodiment disclosed.
24. An expression vector or plasmid according to Claim 11 and substantially as herein described with reference to any embodiment disclosed.
25. A cell according to Claim 12 and substantially as herein described with reference to any embodiment disclosed.
26. An inhibitor according to Claim 14 and substantially as herein described with reference to any embodiment disclosed.
27. Use according to Claim 15 or 16 and substantially as herein described with reference to any embodiment disclosed.
28. A probe comprising a fragment of the isolated nucleic acid of claim 1 or of the amino acid sequence of claim 2. INTELLECTUAL PROPERTY OFFICE j OFNZ -1 MAY 2000 </div>